$0.97
Bio Path is a biotechnology business based in the US. Bio Path shares (BPTH) are listed on the NASDAQ and all prices are listed in US Dollars. Bio Path employs 10 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Bio Path stock
How to buy Bio Path stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BPTH. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Bio Path stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Bio Path stock price (NASDAQ: BPTH)
Use our graph to track the performance of BPTH stocks over time.Bio Path shares at a glance
Latest market close | $0.97 |
---|---|
52-week range | $0.92 - $21.60 |
50-day moving average | $1.63 |
200-day moving average | $5.11 |
Wall St. target price | $20.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-14.19 |
Is it a good time to buy Bio Path stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Bio Path price performance over time
Historical closes compared with the close of $0.971 from 2024-09-05
1 week (2024-08-30) | -1.58% |
---|---|
1 month (2024-08-06) | -32.10% |
3 months (2024-06-06) | -65.07% |
6 months (2024-03-06) | -84.92% |
1 year (2023-09-06) | 155.53% |
---|---|
2 years (2022-09-06) | -73.03% |
3 years (2021-09-03) | 5.56 |
5 years (2019-09-06) | 10.98 |
Bio Path financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -140.03% |
Return on equity TTM | -366.18% |
Profit margin | 0% |
Book value | $0.57 |
Market Capitalization | $2.5 million |
TTM: trailing 12 months
Bio Path share dividends
We're not expecting Bio Path to pay a dividend over the next 12 months.
Have Bio Path's shares ever split?
Bio Path's shares were split on a 1:20 basis on 22 February 2024. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bio Path shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Bio Path shares which in turn could have impacted Bio Path's share price.
Bio Path share price volatility
Over the last 12 months, Bio Path's shares have ranged in value from as little as $0.92 up to $21.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bio Path's is 0.242. This would suggest that Bio Path's shares are less volatile than average (for this exchange).
Bio Path overview
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas. .
Frequently asked questions
nullWhat percentage of Bio Path is owned by insiders or institutions?
Currently 0.067% of Bio Path shares are held by insiders and 5.589% by institutions. How many people work for Bio Path?
Latest data suggests 10 work at Bio Path. When does the fiscal year end for Bio Path?
Bio Path's fiscal year ends in December. Where is Bio Path based?
Bio Path's address is: 4710 Bellaire Boulevard, Bellaire, TX, United States, 77401 What is Bio Path's ISIN number?
Bio Path's international securities identification number is: US09057N3008 What is Bio Path's CUSIP number?
Bio Path's Committee on Uniform Securities Identification Procedures number is: 09057N300
More guides on Finder
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
7 best day trading platforms of 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Trading for beginners: 11 best trading platforms to get started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 best international stock brokers to invest in foreign assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 best discount brokers of 2024 for low-cost trading and investing
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
10 best stock apps of 2024 to elevate your mobile trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
5 top graphene stocks to invest in today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question